This week’s News Flash highlights five clinically useful publications appearing in the August literature. The emphasis is on treatment persistence, body composition, oral obesity medications, and practical decisions about treatment goals. 1. Why Do Patients Stop GLP-1 Medications? A New National Survey Adds Real-World Detail Evidence status: Peer-reviewed national survey A newly published U.S. survey
1. What happens after stopping Wegovy or Zepbound? Withdrawal trials show that substantial weight regain is common after semaglutide or tirzepatide is stopped. The evidence supports planning maintenance before treatment ends rather than assuming the goal weight marks the end of care. Full article: https://belite.com/what-happens-after-stopping-wegovy-zepbound/ 2. How much muscle is lost on GLP-1 treatment? Most
Bottom line Survodutide, an investigational weekly dual glucagon/GLP-1 receptor agonist, produced significantly greater weight loss than placebo in the Phase 3 SYNCHRONIZE-1 trial. The evidence makes it a credible future obesity treatment, but it is not FDA approved, has no established place relative to Wegovy or Zepbound, and should not be purchased as an
Bottom line After a comprehensive review, the FDA reported that it did not find an increased risk of suicidal ideation or behavior associated with GLP-1 receptor agonists and requested removal of that warning from labeling for Saxenda, Wegovy, and Zepbound. This is reassuring, but new depression, suicidal thoughts, or major behavioral change still requires
Bottom line In the 72-week SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide in adults with obesity or overweight without diabetes. That establishes greater average efficacy under the trial conditions. It does not make tirzepatide the best choice for every patient because treatment selection also depends on indication, contraindications, tolerability, coverage, cardiovascular
Bottom line Some lean mass is usually lost during substantial weight reduction, whether weight loss occurs through medication, diet, or surgery. In the SURMOUNT-1 body-composition substudy, about 75% of the weight lost with tirzepatide (Zepbound) was fat mass and about 25% was lean mass. Lean mass is not identical to skeletal muscle, and preserving strength
